# AEGEA Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aegea-medical

- Industry: Medical Devices & Equipment
- Headquarters: Menlo Park, US
- Website: www.aegeamedical.com
- Total disclosed funding: $96M
- Latest round: Series D (Jan 2, 2018)
- Investors on record: 6

## About

Based in the US, AEGEA Medical, Inc. develops innovative medical devices focused on solutions for women's health, particularly in managing heavy menstrual bleeding with advanced treatment technologies.AEGEA Medical, Inc. specializes in developing medical devices for treating heavy menstrual bleeding, and was founded in 2008 in Menlo Park, US. The company has undergone a strategic shift and was acquired by The Cooper Companies Inc in February 2021, with financial terms undisclosed. The firm has completed a total of 8 deals, with the latest funding round occurring on February 2, 2021, led by Solas BioVentures, raising USD 17.00 mn, bringing the total amount raised to USD 17.00 mn.AEGEA Medical, Inc. offers the Mara Water Vapor Ablation System, designed for the in-office treatment of menorrhagia in premenopausal women. This system employs water vapor to ablate the endometrial lining of the uterus, effectively addressing heavy menstrual bleeding caused by benign conditions. The Mara system is adaptable for various anatomical situations, including uterine cavity lengths greater than 10 cm and specific myomas up to 4 cm. Primary customers include healthcare professionals and clinics specializing in women's health, particularly in North America and Europe.AEGEA Medical's revenue is primarily generated from the sale of the Mara Water Vapor Ablation System, marketed to healthcare providers and clinics offering gynecological services. The sales model is direct-to-consumer, where medical professionals purchase the system and necessary disposable components for treatment. Revenue is generated per procedure, aligning with the clinical needs of healthcare providers integrating the system into their treatment plans.Looking ahead, AEGEA Medical plans to expand its product offerings and market reach. Following the acquisition in February 2021, there are initiatives to launch new products designed to enhance women's health solutions. Expansion efforts are aimed at increasing market penetration in both existing and new geographic regions, with a focus on North America and Europe. The recent funding of USD 17.00 mn will support these growth strategies, facilitating product development and market entry initiatives.

## Funding rounds

- Series D, Jan 2, 2018, $40M — Alloy Ventures, Delphi Ventures, Medtronic Ventures, BioMed Ventures, Perceptive Advisors, Solas BioVentures
- Series C, Dec 27, 2017, $4M — Alloy Ventures, Delphi Ventures, Medtronic Ventures, BioMed Ventures, Perceptive Advisors, Solas BioVentures
- Series C, May 4, 2015, $36M — Alloy Ventures, Delphi Ventures, Medtronic Ventures, BioMed Ventures, Solas BioVentures
- Series B, May 24, 2011, $13M — Alloy Ventures, Delphi Ventures, Medtronic Ventures
- Series A, Mar 5, 2008, $2.1M — Alloy Ventures, Delphi Ventures

## Investors

- Alloy Ventures (https://capitalatlas.ai/funds/alloy-ventures) — Series A, Series B, Series C, Series D
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series A, Series B, Series C, Series D
- Medtronic Ventures (https://capitalatlas.ai/funds/medtronic-ventures) — Series B, Series C, Series D
- BioMed Ventures — Series C, Series D
- Solas BioVentures (https://capitalatlas.ai/funds/solas-bioventures) — Series C, Series D
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C, Series D